All In Biotech

Drug Trial Radar · NCT05013632

COVID-19 International Drug Pregnancy Registry

COVID-19 International Drug Pregnancy Registry (COVID-PR)

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Dec 1, 2021

Primary completion

Sep 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
PregistryIndustry
Sponsor type
Industry
First posted
Aug 19, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.

Conditions

  • Covid19

Interventions

  • Antiviral AgentsDrug

    Antiviral medications indicated for the treatment of mild to severe COVID-19

  • Monoclonal antibodyDrug

    Monoclonal antibodies indicated for the treatment of mild to severe COVID-19

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Obstetric outcomesTime frame: 1 year
  2. Neonatal outcomesTime frame: 1 year
  3. Infant weightTime frame: 1 year
  4. Infant developmental milestonesTime frame: 1 year
  5. Infant heightTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pregistry

    Los Angeles, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.